首页> 外文期刊>Revista Cubana de Hematología, Inmunología y Hemoterapia >AML-1/ETO fusion gene and mutation NPM-1A in myeloid chronic leukemia in myeloid blast crisis
【24h】

AML-1/ETO fusion gene and mutation NPM-1A in myeloid chronic leukemia in myeloid blast crisis

机译:髓样疾患危机中髓样慢性白血病中的AML-1 / ETO融合基因和NPM-1A突变

获取原文
           

摘要

Chronic myeloid leukemia is a clonal myeloproliferative neoplasm which generally and progressively goes through three phases: chronic, accelerated and blast crisis. About 80 % of patients with chronic myeloid leukemia are diagnosed in chronic phase, 10 % in accelerated phase and 10 % in blast crisis. The presence of Philadelphia chromosome and the formation of BCR/ABL fusion gene, resulting in the chimeric protein pBCR/ABL, generates a large genomic instability and the acquisition of additional chromosomal and molecular alterations. Some molecular alterations, which are usually present in other hematological malignancies, could be acquired during the progression of chronic myeloid leukemia to blast crisis. This report presents the case of a patient with de novo chronic myeloid leukemia in blast crisis, with positivity of BCR/ABL fusion gene, AML-1/ETO fusion gene and mutation NPM-1A. 
机译:慢性粒细胞白血病是一种克隆性骨髓增生性肿瘤,通常并逐步经历三个阶段:慢性,加速和爆炸性危机。大约80%的慢性粒细胞白血病患者被诊断为慢性期,10%处于加速期,10%处于急变期。费城染色体的存在和BCR / ABL融合基因的形成,导致嵌合蛋白pBCR / ABL,产生了较大的基因组不稳定性,并获得了额外的染色体和分子改变。在慢性粒细胞白血病发展为爆炸性危机期间,可能会获得其他血液恶性肿瘤中通常存在的一些分子改变。该报告介绍了一个新发的慢性骨髓性白血病患者,该患者处于爆炸危险中,具有BCR / ABL融合基因,AML-1 / ETO融合基因和NPM-1A突变阳性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号